Does Z41.8 require prior authorization?

No, Z41.8 does not require prior authorization (low confidence). No active coverage policies found for this code.

Backwork Sign up free

`Z41.8`, Encounter for other procedures for purposes other than remedying health state

ICD-10-CM

Prior Authorization

No Prior Auth Required

No active coverage policies found for this code (low confidence)

Documentation Required

Providers must maintain patient weight in kilograms, ESA units administered per kilogram, and medical justification for any ESA doses exceeding usual doses.
The medical record must include the ordering provider's assessment related to the visit complaint, relevant medical history, results of pertinent tests/procedures, and a signed and dated office visit record or operative report.
For all patients receiving ESAs the medical record must document hemoglobin (Hgb) or hematocrit (Hct) and evidence of adequate iron stores.

Dialysis patient records must include dialysis schedule and Hgb/Hct immediately prior to the billing period; home dialysis patients additionally must have a care plan, evidence of home monitoring (including records of ESA supplied and doses administered), patient instructions, and patient selection protocol.

For CKD (non-dialysis) patients documentation must include serum creatinine, creatinine clearance, or estimated GFR.

For patients with myelodysplastic syndrome (MDS) documentation must include a bone marrow biopsy report (or a physician statement of MDS if ESA therapy was initiated prior to 2007-12-01), date of ESA initiation, and response to therapy (change in Hgb/Hct and transfusion requirements).

Key Coverage Criteria

Administration of erythropoiesis stimulating agents (ESAs) billed with HCPCS J0881, J0882, J0885, J0886, Q4081, Q5105, or Q5106 for patients with anemia related to ESRD, chronic kidney disease (CKD), chemotherapy, radiation, or myelodysplastic syndrome (MDS), when the use meets the coverage criteria in the applicable LCD.
Use of ESAs for chemotherapy-induced, radiation-induced, or non-chemo/non-radiation anemia should be identified on non-ESRD claims by reporting modifier EA (chemo-induced), EB (radio-induced), or EC (non-chemo/radio).
ESA administration may qualify as a Home Health service only when the beneficiary is receiving the ESA for a covered indication specified in the LCD.
Billing and coding for intravenous immunoglobulin (IVIG) should follow the Local Coverage Determination (LCD) L34580 and the billing/coding guidelines in this article as a complement to that LCD.
Off-label IVIG use may be billed when supported by the applicable Local Coverage Determination (LCD) and by documentation of medical necessity; off-label is defined as not in Medicare-approved compendia or the FDA label.
IVIG may be used in bone marrow/stem cell transplantation when the recipient was CMV seropositive before transplantation, or after allogeneic transplantation for hematologic neoplasm when both donor and recipient were CMV seronegative.

11 Active Policies

CGS-J15-L40386, Erythropoiesis Stimulating Agents (ESA)

J15

CGS-J15-L34356, Erythropoiesis Stimulating Agents (ESA)

J15

CGS-J18-L34356, Erythropoiesis Stimulating Agents (ESA)

J18

CGS-J18-L40386, Erythropoiesis Stimulating Agents (ESA)

J18

A59105, Billing and Coding: Off-Label Use of Intravenous Immune Globulin (IVIG)

NGS-J6-L39314, Off-Label Use of Intravenous Immune Globulin (IVIG)

NGS-JK-L39314, Off-Label Use of Intravenous Immune Globulin (IVIG)

AETNA-CPB-0231, Grenz Ray Therapy for Skin Disorders

A56462, Billing and Coding: Erythropoiesis Stimulating Agents (ESA)

A56658, Billing and Coding: Cosmetic and Reconstructive Surgery

A56718, Billing and Coding: Intravenous Immunoglobulin (IVIG)

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about Z41.8 Sign up free

Z41.8, Encounter for other procedures for purposes other than remedying health state